What is the main purpose of this 8-K filing by Eli Lilly?

The main purpose of this 8-K filing by Eli Lilly and Company is to officially report its financial results and condition for the quarter ended March 31, 2023. It serves as a notification to investors and the public about the company's performance during that period.

Where can I find the detailed financial results for Q1 2023?

The detailed financial results for the quarter ended March 31, 2023, are contained within the press release attached as Exhibit 99.1 to this 8-K filing. Investors should review this exhibit for specific revenue, earnings, and other financial performance data.

Does this 8-K filing contain new financial guidance for the rest of the year?

This 8-K filing itself does not contain the specific financial guidance. The guidance, if any, would typically be disclosed within the accompanying press release (Exhibit 99.1). Investors should carefully read the press release to see if Eli Lilly provided any updated financial outlook or projections for the remainder of 2023.

What does it mean that the information is 'furnished' and not 'filed'?

When information is furnished under Item 2.02, it means the company is providing the information to the SEC, but it is not subject to the same level of liability under Section 18 of the Exchange Act as if it were 'filed'. It also means the information won't automatically be incorporated into the company's registration statements. While this is a standard disclosure method, investors still rely on this information as it represents the company's official earnings release.

LLY 8-K: Earnings & Results

Summary

Eli Lilly and Company (LLY) filed an 8-K on April 27, 2023, primarily to report its financial results for the quarter ended March 31, 2023. The report references an attached press release (Exhibit 99.1) containing the detailed financial outcomes for the period. While the 8-K itself does not contain the specific financial figures, it signals the public disclosure of the company's performance, which investors should review in the accompanying press release for insights into revenue, earnings, and other key financial metrics. This filing is routine for publicly traded companies and serves as a formal notification of material events. For investors, the crucial information lies within the unaudited interim financial results for the first quarter of 2023, which will provide an update on the company's operational and financial condition. Key areas to scrutinize in the press release will include product sales performance, earnings per share (EPS), any forward-looking guidance, and significant developments or challenges encountered during the quarter.

Key Highlights

1Eli Lilly & Co. (LLY) filed an 8-K on April 27, 2023, to report financial results.
2The report incorporates a press release (Exhibit 99.1) dated April 27, 2023, detailing Q1 2023 financial performance.
3This filing is a standard procedure to inform investors of quarterly earnings and financial condition.
4Investors need to refer to the Exhibit 99.1 press release for specific Q1 2023 financial results and operational details.
5The filing does not contain detailed financial figures directly but references the source where they are published.
6The information provided is furnished and not deemed 'filed' for certain SEC purposes, meaning standard liability provisions may not apply to the furnished content.

ELI LILLY & Co 8-K Report, Financial Results (Apr 27, 2023)

Summary

Key Highlights

Frequently Asked Questions